Investigating FDA-approved drugs in an animal model of KCNT1-childhood epilepsy to identify potential new therapies for treating children

Investigating FDA-approved drugs in an animal model of KCNT1-childhood epilepsy to identify potential new therapies for treating children

Chief Investigator: Professor Leanne Dibbens Funding Amount: $ 100,000 Recipient: University of South Australia Overview: KCNT1 mutations cause one of the most severe forms of epilepsy in children, resulting in

Overcoming drug resistance in childhood seizure and psychiatric disorders caused by potassium channels

Chief Investigator: Professor Leanne Dibbens Research Area: Improving children’s mental health and the impact of developmental disorders. Basic Science Funding Amount: $100,000 Recipient: University of South Australia Overview: Children with